Effect of Intravenous Adenosine on neuro-psychological dysfunction post coronary artery bypass surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002794-79-GB

Enrollment

Registered

2006-01-16

Start date

2006-02-21

Completion date

Unknown

Last updated

2019-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuro psychological dysfunction post cardiac by-pass surgery

Interventions

Trade Name: Adenosine (Adenocor) Product Name: Adenocor Pharmaceutical Form: Intravenous infusion INN or Proposed INN: Adenocor Current

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged 18 or older having first time isolated CABG Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Steroid usage, pregnancy, Atrial venticular black or sinus node dysfunction - Bronchoconstrictive disease/hypersensitivity to adenosine

Design outcomes

Primary

Measure	Time frame
Main Objective: To assess if adenosine has a neuro protective effect in patients undergoing cardiac by-pass surgery;Secondary Objective: Assess the changes in haemodynamic status ie inotropic requirements etc; Primary end point(s): Primary endpoint To assess whether adenosine has a neuro-protective effect which is clinically translated into improvement of neuro-psychometric dysfunction when tested by the “CANTAB” neuro-psychometric tests. Secondary endpoint Will assess the changes in the haemodynamic status, inotropic requirement, mediastinal haemorrhage and blood product requirement of patients treated with adenosine.	—

Measure

Time frame

Main Objective: To assess if adenosine has a neuro protective effect in patients undergoing cardiac by-pass surgery;Secondary Objective: Assess the changes in haemodynamic status ie inotropic requirements etc; Primary end point(s): Primary endpoint To assess whether adenosine has a neuro-protective effect which is clinically translated into improvement of neuro-psychometric dysfunction when tested by the “CANTAB” neuro-psychometric tests. Secondary endpoint Will assess the changes in the haemodynamic status, inotropic requirement, mediastinal haemorrhage and blood product requirement of patients treated with adenosine.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026